Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Esperion Therapeutics stock price, quote, forecast and news

ESPR
US29664W1053
A1W1SJ

Price

1.61
Today +/-
-0.04
Today %
-2.45 %
P

Esperion Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Esperion Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Esperion Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Esperion Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Esperion Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Esperion Therapeutics Stock Price History

DateEsperion Therapeutics Price
9/25/20241.61 undefined
9/24/20241.65 undefined
9/23/20241.63 undefined
9/20/20241.68 undefined
9/19/20241.75 undefined
9/18/20241.74 undefined
9/17/20241.78 undefined
9/16/20241.76 undefined
9/13/20241.91 undefined
9/12/20241.75 undefined
9/11/20241.74 undefined
9/10/20241.73 undefined
9/9/20241.70 undefined
9/6/20241.65 undefined
9/5/20241.72 undefined
9/4/20241.82 undefined
9/3/20241.83 undefined
8/30/20241.83 undefined
8/29/20241.75 undefined
8/28/20241.70 undefined

Esperion Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Esperion Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Esperion Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Esperion Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Esperion Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Esperion Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Esperion Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Esperion Therapeutics’s growth potential.

Esperion Therapeutics Revenue, EBIT and net profit per share

DateEsperion Therapeutics RevenueEsperion Therapeutics EBITEsperion Therapeutics Net Income
2029e982.26 M undefined0 undefined0 undefined
2028e1.37 B undefined860.98 M undefined698.5 M undefined
2027e886.07 M undefined472.26 M undefined381.28 M undefined
2026e639.2 M undefined186.05 M undefined182.2 M undefined
2025e442.53 M undefined57.49 M undefined43.71 M undefined
2024e357.31 M undefined44.21 M undefined-36.67 M undefined
2023116.33 M undefined-155.56 M undefined-209.25 M undefined
202275.5 M undefined-179.5 M undefined-233.7 M undefined
202178.4 M undefined-213.4 M undefined-269.1 M undefined
2020227.5 M undefined-121.4 M undefined-143.6 M undefined
2019148.4 M undefined-93.1 M undefined-97.2 M undefined
20180 undefined-204.6 M undefined-201.8 M undefined
20170 undefined-169 M undefined-167 M undefined
20160 undefined-76.2 M undefined-75 M undefined
20150 undefined-50 M undefined-49.8 M undefined
20140 undefined-36.2 M undefined-36.4 M undefined
20130 undefined-22.8 M undefined-26.1 M undefined
20120 undefined-10.2 M undefined-11.7 M undefined
20110 undefined-10.2 M undefined-10.8 M undefined
20020 undefined-27.3 M undefined-28.7 M undefined
20010 undefined-27.3 M undefined-24.9 M undefined
20000 undefined-26 M undefined-50.4 M undefined
19990 undefined-11 M undefined-10.7 M undefined
19980 undefined-2.4 M undefined-2.1 M undefined

Esperion Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1998199920002001200220112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000000000.150.230.080.080.120.360.440.640.891.370.98
--------------53.38-65.64-3.8554.67207.7623.8144.5738.6554.40-28.22
--------------99.1282.0564.0062.93------
00000000000000225644873000000
-2-11-26-27-27-10-10-22-36-50-76-169-204-93-121-213-179-15544571864728600
--------------62.84-53.30-273.08-238.67-133.6212.3212.9029.1153.2762.87-
-2-10-50-24-28-10-11-26-36-49-75-167-201-97-143-269-233-209-36431823816980
-400.00400.00-52.0016.67-64.2910.00136.3638.4636.1153.06122.6720.36-51.7447.4288.11-13.38-10.30-82.78-219.44323.26109.3483.20-
1.51.825.827.329.30.30.37.916.42222.523.926.827.127.528.966.4103.11000000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Esperion Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Esperion Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199819992000200120022011201220132014201520162017201820192020202120222023
                                   
12.55.970.270.344.91.66.560.1105.8212.3211.6200.2136200.8305259.3166.982.25
00000000000000022.933.748.49
000000000000000000
0000000000000016.134.435.265.62
0.10.11.110.40.30.60.60.92.123.76.610.924.812.310.94.7
12.6671.371.345.31.97.160.7106.7214.4213.6203.9142.6211.7345.9328.9246.7201.07
0.822.53.330.30.10.10.80.80.70.40.52.77.32.61.24.68
000000017.535.780.330.973.40.200000
000000000000000000
0000010010010010010010010010010010010010056
003.53.13.10000000000000
000.50.6000000000005000
0.826.576.10.40.217.736.681.231.773.90.82.87.452.71.34.73
13.4877.878.351.42.37.378.4143.3295.6245.3277.8143.4214.5353.3381.6248205.8
                                   
0.10.10002424000000000.10.10.12
0.020.020.110.130.13000.140.240.440.460.640.680.720.80.961.071.15
-2.1-12.8-40.4-65.3-94-30.2-42-68.1-104.4-154.2-229.2-396.3-598.1-695.3-838.8-1,106.4-1,340-1,549.28
-0.1-0.9-2.6-1.4-0.7000-0.1-0.5-0.2-0.8-0.300000
000000000000000000
13.22.967.766.438.7-6-17.474133.5287.2228.6244.779.119.9-41.1-141.9-268.7-400
0.11.43.92.91.70.70.52.220.74.620.444.928.95217.62331.72
0.112.52.62.20.61.222.83.39.311.719.429.83538.84164.28
0000000.30000007.47.11728.360.23
00000015.200000000000
00.50.70.91.10000.61.61.71000000
0.22.97.16.451.317.24.25.45.615.633.164.366.194.173.492.3156.22
02.335.57.76.97.504.22.71000179.4258.3259.9261.6
000000000000000000
0000000000000128.4176246.9219.5242.97
02.335.57.76.97.504.22.7100128.4355.4505.2479.4504.57
0.25.210.111.912.78.224.74.29.68.316.633.164.3194.5449.5578.6571.7660.79
13.48.177.878.351.42.27.378.2143.1295.5245.2277.8143.4214.4408.4436.7303260.79
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Esperion Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Esperion Therapeutics's financial health and stability.

Assets

Esperion Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Esperion Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Esperion Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Esperion Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19981999200020012002null2011201220132014201520162017201820192020202120222023
-2-10-27-24-28-31-10-11-26-36-49-74-166-201-97-143-269-233-209
0012110000000000000
0000000000000000000
013-1020030-291629-7-4-52-313
0051110157263237475990817671
0000000000000000000
0000000000000000000
-1-7-17-22-26-27-9-10-18-32-38-47-131-148-70-85-263-174-135
0-1-1-2-10000000000-13000
0-1-2-2-5-5000-21-36-16010-351406421-50842
0000-4-4900-20-35-15910-351406534-50842
0000000000000000000
020210015000-1-1-10280000
150832206860899219101651111-482229065
15284251676158997190-1163101362012683250
00000000040000124-2945-58-15
0000000000000000000
12-6640-29-8-145028-7-39-32130137-46-134-42
-2.78-9.41-19.29-24.79-27.720-9.1-10.82-18.14-32.89-38.49-47.82-131.32-148.79-71.29-98.55-263.81-174.83-135.49
0000000000000000000

Esperion Therapeutics stock margins

The Esperion Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Esperion Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Esperion Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Esperion Therapeutics's sales revenue. A higher gross margin percentage indicates that the Esperion Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Esperion Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Esperion Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Esperion Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Esperion Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Esperion Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Esperion Therapeutics Margin History

Esperion Therapeutics Gross marginEsperion Therapeutics Profit marginEsperion Therapeutics EBIT marginEsperion Therapeutics Profit margin
2029e62.81 %0 %0 %
2028e62.81 %62.89 %51.02 %
2027e62.81 %53.3 %43.03 %
2026e62.81 %29.11 %28.5 %
2025e62.81 %12.99 %9.88 %
2024e62.81 %12.37 %-10.26 %
202362.81 %-133.72 %-179.87 %
202264.24 %-237.75 %-309.54 %
202181.89 %-272.19 %-343.24 %
202098.99 %-53.36 %-63.12 %
201962.81 %-62.74 %-65.5 %
201862.81 %0 %0 %
201762.81 %0 %0 %
201662.81 %0 %0 %
201562.81 %0 %0 %
201462.81 %0 %0 %
201362.81 %0 %0 %
201262.81 %0 %0 %
201162.81 %0 %0 %
200262.81 %0 %0 %
200162.81 %0 %0 %
200062.81 %0 %0 %
199962.81 %0 %0 %
199862.81 %0 %0 %

Esperion Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Esperion Therapeutics earnings per share therefore indicates how much revenue Esperion Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Esperion Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Esperion Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Esperion Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Esperion Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Esperion Therapeutics Revenue, EBIT and net profit per share

DateEsperion Therapeutics Sales per ShareEsperion Therapeutics EBIT per shareEsperion Therapeutics Earnings per Share
2029e5.01 undefined0 undefined0 undefined
2028e6.98 undefined0 undefined3.56 undefined
2027e4.52 undefined0 undefined1.94 undefined
2026e3.26 undefined0 undefined0.93 undefined
2025e2.26 undefined0 undefined0.22 undefined
2024e1.82 undefined0 undefined-0.19 undefined
20231.13 undefined-1.51 undefined-2.03 undefined
20221.14 undefined-2.7 undefined-3.52 undefined
20212.71 undefined-7.38 undefined-9.31 undefined
20208.27 undefined-4.41 undefined-5.22 undefined
20195.48 undefined-3.44 undefined-3.59 undefined
20180 undefined-7.63 undefined-7.53 undefined
20170 undefined-7.07 undefined-6.99 undefined
20160 undefined-3.39 undefined-3.33 undefined
20150 undefined-2.27 undefined-2.26 undefined
20140 undefined-2.21 undefined-2.22 undefined
20130 undefined-2.89 undefined-3.3 undefined
20120 undefined-34 undefined-39 undefined
20110 undefined-34 undefined-36 undefined
20020 undefined-0.93 undefined-0.98 undefined
20010 undefined-1 undefined-0.91 undefined
20000 undefined-1.01 undefined-1.95 undefined
19990 undefined-6.11 undefined-5.94 undefined
19980 undefined-1.6 undefined-1.4 undefined

Esperion Therapeutics business model

Esperion Therapeutics Inc is a company specialized in researching and developing innovative therapies for the treatment of heart diseases. It was founded in 2008 and is headquartered in Ann Arbor, Michigan. History: The founding of Esperion is closely connected with the history of another pharmaceutical company, Pfizer. In 2003, Pfizer introduced the drug Lipitor, used for treating high cholesterol levels. Lipitor quickly became one of the most successful medications worldwide, generating billions in revenue over the following years. Esperion Therapeutics Inc was founded to develop an alternative to Lipitor that would be better tolerated and potentially more effective. The company relied on the expertise of Dr. Roger Newton, the former research director at Pfizer involved in the development of Lipitor. Business model: Esperion's business model is based on acquiring patents for new compounds and then investigating these compounds in clinical trials. If a compound shows promise, Esperion can apply for approval from the US Food and Drug Administration (FDA) and bring the medication to market. The company has also formed a partnership with Daiichi-Sankyo to market its products in Japan and other Asian countries. Segments: Esperion focuses on developing therapies for the treatment of hyperlipidemia, or high cholesterol levels. This means the company develops medications that lower LDL cholesterol levels and reduce the risk of heart and vascular diseases. One promising compound from Esperion is ETC-1002. This medication is currently being tested in clinical trials and has the potential to be an effective alternative to conventional statins, as it does not have the same undesired effects. Other products: Esperion also has a division called Esperion Diabetes Solutions, which focuses on developing therapies for the treatment of type 2 diabetes. However, this is still in the development stage. Additionally, the company has another compound in clinical development called Bempedoic Acid. This medication acts at the cellular level to inhibit cholesterol synthesis in the body. Conclusion: Esperion Therapeutics is a company specializing in the development of innovative therapies for the treatment of heart diseases. The company focuses on lowering LDL cholesterol levels and reducing the risk of heart and vascular diseases. Esperion's promising product is ETC-1002, which has the potential to be an effective alternative to conventional statins. Through its partnership with Daiichi-Sankyo, the company also has access to Asian markets. Esperion Therapeutics is one of the most popular companies on Eulerpool.com.

Esperion Therapeutics SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Esperion Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Esperion Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Esperion Therapeutics shares outstanding

The number of shares was Esperion Therapeutics in 2023 — This indicates how many shares 103.107 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Esperion Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Esperion Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Esperion Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Esperion Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Esperion Therapeutics.

Esperion Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.19 -0.33  (-75.63 %)2024 Q2
3/31/20240.05 0.34  (612.79 %)2024 Q1
12/31/2023-0.49 -0.5  (-1.58 %)2023 Q4
9/30/2023-0.44 -0.37  (16.08 %)2023 Q3
6/30/2023-0.62 -0.46  (26.23 %)2023 Q2
3/31/2023-0.67 -0.79  (-18.73 %)2023 Q1
12/31/2022-0.86 -0.76  (11.37 %)2022 Q4
9/30/2022-0.94 -0.81  (14.09 %)2022 Q3
6/30/2022-0.94 -1.05  (-11.17 %)2022 Q2
3/31/2022-1.06 -0.93  (12.64 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Esperion Therapeutics stock

Eulerpool World ESG Rating (EESG©)

35/ 100

🌱 Environment

39

👫 Social

31

🏛️ Governance

35

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Esperion Therapeutics list of shareholders

%
Name
Stocks
Change
Date
4.68559 % Bellevue Asset Management AG9,194,0644,989,8001/19/2024
4.65276 % Wasatch Global Investors Inc9,129,647238,5443/31/2024
3.91709 % Two Seas Capital LP7,686,12013,95012/31/2023
2.61836 % The Vanguard Group, Inc.5,137,750396,38812/31/2023
2.28367 % Two Sigma Investments, LP4,481,0101,450,09712/31/2023
1.93217 % Meditor Capital Management Limited3,791,30003/31/2024
1.75795 % Millennium Management LLC3,449,451-2,344,57812/31/2023
1.43235 % Platinum Asset Management2,810,555-378,96212/31/2023
0.97813 % BlackRock Institutional Trust Company, N.A.1,919,28618,08912/31/2023
0.94282 % Tang Capital Management, LLC1,850,000012/31/2023
1
2
3
4
5
...
10

Esperion Therapeutics Executives and Management Board

Mr. Sheldon Koenig57
Esperion Therapeutics President, Chief Executive Officer, Director (since 2020)
Compensation 3.8 M
Dr. JoAnne Foody58
Esperion Therapeutics Chief Medical Officer
Compensation 1.53 M
Mr. Benjamin Looker41
Esperion Therapeutics General Counsel
Compensation 1.29 M
Mr. Stephen Rocamboli51
Esperion Therapeutics Independent Director
Compensation 187,149
Mr. J. Martin Carroll73
Esperion Therapeutics Independent Chairman of the Board
Compensation 181,649
1
2
3

Esperion Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Daiichi Sankyo Stock
Daiichi Sankyo
SupplierCustomer0,950,540,610,52-0,380,51
Otsuka Holdings Stock
Otsuka Holdings
SupplierCustomer0,900,710,640,500,620,43
1

Most common questions regarding Esperion Therapeutics

What values and corporate philosophy does Esperion Therapeutics represent?

Esperion Therapeutics Inc represents a commitment to improving cardiovascular health through innovative therapies. The company's corporate philosophy centers around developing effective treatments for patients with high levels of low-density lipoprotein cholesterol (LDL-C) and other cardiovascular risks. With a focus on research and development, Esperion Therapeutics Inc strives to deliver transformative medicines that address unmet medical needs. The company's dedication to patient well-being, scientific excellence, and enhancing patient outcomes drives its pursuit of novel therapies. Esperion Therapeutics Inc's values include integrity, collaboration, and a patient-centric approach, as it aims to make a positive impact on cardiovascular health worldwide.

In which countries and regions is Esperion Therapeutics primarily present?

Esperion Therapeutics Inc. is primarily present in the United States.

What significant milestones has the company Esperion Therapeutics achieved?

Esperion Therapeutics Inc, a leading biopharmaceutical company, has achieved several significant milestones in recent years. The company successfully received FDA approval for its groundbreaking drug, Nexletol, in February 2020. This milestone marked Esperion's entry into the cardiovascular market, providing healthcare professionals with an innovative option to address high cholesterol levels. Additionally, Esperion Therapeutics Inc has made remarkable progress in advancing its pipeline, including the development of other potential therapeutic candidates. With its continued commitment to scientific excellence and dedication to improving patients' lives, Esperion Therapeutics Inc remains a prominent player in the pharmaceutical industry.

What is the history and background of the company Esperion Therapeutics?

Esperion Therapeutics Inc is a biopharmaceutical company specializing in the research and development of therapies for cardiovascular diseases. Founded in 2008 and based in the United States, Esperion has been devoted to delivering innovative treatments to patients with high-risk cardiovascular conditions. With a focus on cholesterol management, the company aims to develop and commercialize convenient, cost-effective, and efficient therapies. Esperion Therapeutics Inc has a rich history of pioneering advancements in cardiovascular medicine, fueled by a team of dedicated scientists and professionals. Through its commitment to improving patient outcomes, Esperion continues to make significant strides in the field of cardiovascular treatment.

Who are the main competitors of Esperion Therapeutics in the market?

The main competitors of Esperion Therapeutics Inc in the market are AstraZeneca, Pfizer, Merck & Co., Amgen, and Regeneron Pharmaceuticals.

In which industries is Esperion Therapeutics primarily active?

Esperion Therapeutics Inc is primarily active in the pharmaceutical industry.

What is the business model of Esperion Therapeutics?

The business model of Esperion Therapeutics Inc revolves around the development and commercialization of innovative cholesterol-lowering therapies. As a pharmaceutical company, Esperion focuses on researching, designing, and delivering safe and effective medicines to help patients manage and improve their lipid profiles. By utilizing their expertise in lipid management, Esperion aims to address the unmet medical needs of individuals with hypercholesterolemia and other cardiovascular conditions. Through strategic collaborations, clinical trials, and regulatory approvals, Esperion Therapeutics Inc strives to introduce novel treatments that can potentially revolutionize the prevention and treatment of cardiovascular diseases.

What is the P/E ratio of Esperion Therapeutics 2024?

The Esperion Therapeutics P/E ratio is -4.53.

What is the P/S ratio of Esperion Therapeutics 2024?

The Esperion Therapeutics P/S ratio is 0.46.

What is the AlleAktien quality score of Esperion Therapeutics?

The AlleAktien quality score for Esperion Therapeutics is 6/10.

What is the revenue of Esperion Therapeutics 2024?

The expected Esperion Therapeutics revenue is 357.31 M USD.

How high is the profit of Esperion Therapeutics 2024?

The expected Esperion Therapeutics profit is -36.67 M USD.

What is the business model of Esperion Therapeutics

Esperion Therapeutics Inc is a biopharmaceutical company that focuses on the research and development of drugs for the treatment of cardiovascular diseases. The company's business model is based on the development of innovative, effective, and safe medications for patients at high cardiovascular risk.

What is the Esperion Therapeutics dividend?

Esperion Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Esperion Therapeutics pay dividends?

The dividend cannot currently be calculated for Esperion Therapeutics or the company does not pay out a dividend.

What is the Esperion Therapeutics ISIN?

The ISIN of Esperion Therapeutics is US29664W1053.

What is the Esperion Therapeutics WKN?

The WKN of Esperion Therapeutics is A1W1SJ.

What is the Esperion Therapeutics ticker?

The ticker of Esperion Therapeutics is ESPR.

How much dividend does Esperion Therapeutics pay?

Over the past 12 months, Esperion Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Esperion Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Esperion Therapeutics?

The current dividend yield of Esperion Therapeutics is .

When does Esperion Therapeutics pay dividends?

Esperion Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Esperion Therapeutics?

Esperion Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Esperion Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Esperion Therapeutics located?

Esperion Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Esperion Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Esperion Therapeutics from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Esperion Therapeutics pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Esperion Therapeutics in the year 2023?

In the year 2023, Esperion Therapeutics distributed 0 USD as dividends.

In which currency does Esperion Therapeutics pay out the dividend?

The dividends of Esperion Therapeutics are distributed in USD.

All fundamentals about Esperion Therapeutics

Our stock analysis for Esperion Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Esperion Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.